Advanced Search
Editorials
View All Editorials
What CMOs Need to Know About the IPO Process

Skills CMOs Need to Support a Successful IPO

BMS on Managing IO Operations and Sparking Joy for Science in Young People

Combining Natural Killer Cells and Synthetic Biology to Fight Solid Tumor Cancers

Takeda’s Approach to Translational Medicine in Immuno-Oncology

How MIT Developed Invisible Remote Monitoring to Enhance Research

Archive Highlight: How Genomics Is Advancing the Next Generation of IO at the Cleveland Clinic

How AstraZeneca Created a Chronic Disease Management System for Patients and Clinicians
Podcasts
View All
Targeted Radiotherapy, Combinations with IO and and the Impact on the Future of Treatment

Regeneron’s Approach to Strategic Collaborations, Licensing and Business Development

Using Neoadjuvant Immune Checkpoint Blockade as a Window into Treatment Response and Primary Resistance

Nobel Laureate Dr Gregg Semenza Presents Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors

Investment and Collaboration Strategies in Cell and Gene Therapy

Investment Trends for the IO 2.0 Wave

Innovative CRISPR Editing to Create Off-the-Shelf Immune Cell Therapies

Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach
Webcasts / Videos
View All
Here is What Patients Would Change About Their Clinical Trials

BMS' Chief Medical Officer Is Cultivating a Patients-First Environment

CSL Behring CEO on Prioritizing Patient-Centric Research and Leading Through the Pandemic

Time's Up: Truly Servicing Diverse Populations in Clinical Trials

Dr Arie Belldegrun Discusses His Vision for Treating Cancer

How Synthetic Biology & Synthetic Circuits In Cell Therapy Can Advance the Field

How MD Anderson is Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
